New Zealand - English - Medsafe (Medicines Safety Authority)

clinect nz pty limited - allopurinol 300mg;   - tablet - 300 mg - active: allopurinol 300mg   excipient: colloidal silicon dioxide croscarmellose sodium magnesium stearate sunset yellow aluminium lake - · allopurinol is mainly used in the management of primary gout or secondary hyperuricaemia associated with chronic gout. it is not, however, used to treat an acute attack of gout as it has no analgesic, antiinflammatory or uricosuric activity and may prolong the attack. if changing therapy from a uricosuric agent alone, the dose should be reduced gradually while allopurinol is introduced. in severe cases of chronic gout, allopurinol can be used together with a uricosuric agent unless the latter is contra-indicated.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

teva uk ltd - allopurinol - oral tablet - 100mg

Malta - English - Medicines Authority

wockhardt uk limited - allopurinol - tablet - allopurinol 100 mg - antigout preparations

Malta - English - Medicines Authority

wockhardt uk limited - allopurinol - tablet - allopurinol 300 mg - antigout preparations

Malta - English - Medicines Authority

pinewood laboratories limited ballymacarbry, clonmel, co. tipperary, ireland - allopurinol - tablet - allopurinol 100 mg - antigout preparations

United Kingdom - English - myHealthbox

milpharm limited - allopurinol - tablets - 100mg - preparations inhibiting uric acid production - it is indicated for reducing urate/uric acid formation in conditions where urate/uric acid deposition has already occurred (e.g. gouty arthritis, skin tophi, nephrolithiasis) or is a predictable clinical risk (e.g. treatment of malignancy potentially leading to acute uric acid nephropathy). the main clinical conditions where urate/uric acid deposition may occur are: idiopathic gout; uric acid lithiasis; acute uric acid nephropathy; neoplastic disease and myeloproliferative disease with high cell turnover rates, in which high urate levels occur either spontaneously, or after cytotoxic therapy; certain enzyme disorders which lead to overproduction of urate, for example: hypoxanthine-guanine phosphoribosyltransferase, including lesch-nyhan syndrome; glucose-6-phosphatase including glycogen storage disease; phosphoribosylpyrophosphate synthetase, phosphoribosylpyrophosphate amidotransferase; adenine phosphoribosyltransferase. allopurinol is indicated for management of 2,8-dihydroxyadenine (2,8-dha) renal stones

United Kingdom - English - myHealthbox

milpharm limited - allopurinol - tablets - 300mg - preparations inhibiting uric acid production - it is indicated for reducing urate/uric acid formation in conditions where urate/uric acid deposition has already occurred (e.g. gouty arthritis, skin tophi, nephrolithiasis) or is a predictable clinical risk (e.g. treatment of malignancy potentially leading to acute uric acid nephropathy). the main clinical conditions where urate/uric acid deposition may occur are: idiopathic gout; uric acid lithiasis; acute uric acid nephropathy; neoplastic disease and myeloproliferative disease with high cell turnover rates, in which high urate levels occur either spontaneously, or after cytotoxic therapy; certain enzyme disorders which lead to overproduction of urate, for example: hypoxanthine-guanine phosphoribosyltransferase, including lesch-nyhan syndrome; glucose-6-phosphatase including glycogen storage disease; phosphoribosylpyrophosphate synthetase, phosphoribosylpyrophosphate amidotransferase; adenine phosphoribosyltransferase. allopurinol is indicated for management of 2,8-dihydroxyadenine (2,8-dha) renal stones r

New Zealand - English - Medsafe (Medicines Safety Authority)

ipca pharma (nz) pty limited - allopurinol 100mg;  ;   - tablet - 100 mg - active: allopurinol 100mg     excipient: lactose maize starch povidone purified water sodium starch glycolate stearic acid - · allopurinol is mainly used in the management of primary gout or secondary hyperuricaemia associated with chronic gout. it is not, however, used to treat an acute attack of gout as it has no analgesic, anti-inflammatory or uricosuric activity and may prolong the attack. if changing therapy from a uricosuric agent alone, the dose should be reduced gradually while allopurinol is introduced. in severe cases of chronic gout, allopurinol can be used together with a uricosuric agent unless the latter is contra-indicated.

New Zealand - English - Medsafe (Medicines Safety Authority)

ipca pharma (nz) pty limited - allopurinol 300mg;  ;   - tablet - 300 mg - active: allopurinol 300mg     excipient: lactose maize starch povidone purified water sodium starch glycolate stearic acid sunset yellow aluminium lake - · allopurinol is mainly used in the management of primary gout or secondary hyperuricaemia associated with chronic gout. it is not, however, used to treat an acute attack of gout as it has no analgesic, anti-inflammatory or uricosuric activity and may prolong the attack. if changing therapy from a uricosuric agent alone, the dose should be reduced gradually while allopurinol is introduced. in severe cases of chronic gout, allopurinol can be used together with a uricosuric agent unless the latter is contra-indicated.

Malta - English - Medicines Authority

accord healthcare ireland ltd euro house, euro business park, little island cork, t45 k857, ireland - allopurinol - tablet - allopurinol 100 mg - antigout preparations